期刊
DIABETES OBESITY & METABOLISM
卷 3, 期 4, 页码 254-258出版社
BLACKWELL SCIENCE LTD
DOI: 10.1046/j.1463-1326.2001.00118.x
关键词
salivatin (salivary peptide P-C); saliva; patients with type 2 diabetes; xerostomia; streptozotocin; BALB/c mice
Aim: Diabetic xerostomia is a typical syndrome in diabetic complication. We have reported that salivatin (salivary peptide P-C) derived from human saliva potentiates glucose-stimulated insulin release and inhibits arginine-stimulated glucagon release. The present study is aimed to Gain further evidence on the physiological role by investigating the diabetic state-induced change in the amount of salivatin. Methods: The amount of salivatin was measured in saliva taken from patients with type 2 diabetes with ELISA and with rabbit antiserum against human salivatin immunocytochemically in sections of parotid glands from streptozotocin-diabetic BALB/c mice. Results: The amount of salivatin after a meal was reduced by diabetes in both human saliva and in the serous secretory granule of mouse parotid gland acinar cells. Conclusions: The above results suggest that salivatin lowers hyperglycaemia after meal and sustains the normal blood glucose levels by incretin-like mechanisms. The function may be damaged by diabetes, and this in turn might make the diabetes worse.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据